XBiotech Inc.

XBIT

Healthcare|Biotechnology|US

$1.89

+0.02 (+1.07%)

DCF Value

$4.08

Tangible Book / Share

$4.21

Cash / Share

$3.59

Clinical Trials (8)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06526377 Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy	Axial Spondyloarthritis, Ankylosing Spondylitis	P2	Not Yet Recruiting	150	RCT, Double-blind	vilamakitug, placebo
NCT06590090 Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment	Rheumatoid Arthritis	P2	Not Yet Recruiting	108	RCT, Double-blind	Natrunix 400 mg, Placebo, Methotrexate (MTX)
NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis	Rheumatoid Arthritis	P2	Completed	243	RCT, Double-blind	Natrunix, Placebo
NCT02357966 Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.	Staphylococcus Aureus Bacteremia	P1P2	Completed	52	RCT, Double-blind	514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II
NCT05363917 Natrunix Versus Methotrexate in Rheumatoid Arthritis	Rheumatoid Arthritis	P2	Unknown	150	RCT, Double-blind	Natrunix with MTX placebo (+folate), Natrunix placebo with MTX (+folate)
NCT04825288 XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer	Pancreatic Cancer	P1P2	Completed	76	RCT, Double-blind	Phase I: XB2001 250 mg, Phase I: XB2001 500 mg, Phase I: XB2001 1000 mg, Phase II: XB2001 1000 mg, Phase II: Placebo
NCT05098080 Hutrukin to Analyze Safety and PK in Healthy Volunteers	Pharmacokinetics	P1	Completed	24	RCT, Open-label	Hutrukin, Placebo
NCT05099510 Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers	Pharmacokinetics	P1	Completed	24	RCT, Open-label	Natrunix, Placebo